Company news

Oncolytics Biotech Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

May 8, 2024

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

May 8, 2024

Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting

April 25, 2024

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

April 11, 2024

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

March 6, 2024

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

March 6, 2024

Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN

March 4, 2024

Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

February 15, 2024

Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort

February 13, 2024

Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors

January 9, 2024

Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024

January 3, 2024

Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS

December 7, 2023

Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep

November 9, 2023

Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC

November 3, 2023

The pancreatic cancer action network selects Oncolytics Biotech® Inc. to receive $5 million Therapeutic Accelerator Award to develop leading-edge treatments

September 26, 2023

Oncolytics Biotech® Reports Second Quarter 2023 Financial Results and Operational Highlights

August 14, 2023

Oncolytics Biotech's® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial

June 21, 2023

Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate

June 4, 2023

Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract

May 24, 2023

Oncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational Highlights

May 4, 2023

Oncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual Meeting

April 25, 2023

Oncolytics Biotech® Announces Filing and Mailing of the Management Information Circular in Connection with the Annual General Meeting of Shareholders

April 11, 2023

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

March 2, 2023

Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer

November 30, 2022

Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium

November 20, 2022

Oncolytics Biotech® Reports Third Quarter 2022 Financial Results and Recent Operational Highlights

November 6, 2022

Oncolytics Biotech® Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting

October 4, 2022

Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors

September 7, 2022

Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights

August 11, 2022

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights

July 27, 2022

Oncolytics Biotech® Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET

June 28, 2022

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors

June 17, 2022

Oncolytics Biotech® to Participate in a Fireside Chat at the 2022 RBC Capital Markets Global Healthcare Conference

May 10, 2022

Oncolytics Biotech® Reports First Quarter 2022 Financial Results and Recent Operational Highlights

May 5, 2022

Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting

May 4, 2022

Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Breast Cancer Meeting

May 2, 2022

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

April 28, 2022

Oncolytics Biotech® to Present at the Bloom Burton & Co. Healthcare Investor Conference

April 21, 2022

Oncolytics Biotech® Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors in Science Translational Medicine

April 14, 2022

Oncolytics Biotech® to Participate in a Fireside Chat at the Canaccord Genuity Horizons in Oncology Virtual Conference

April 12, 2022

Oncolytics Biotech® Announces Positive Long-Term Survival Data from Phase 1b Glioblastoma Multiforme Trial at the AACR Annual Meeting

April 8, 2022

Oncolytics Biotech® Presents New Data Demonstrating Durable Clinical Benefit in Relapsed/Refractory Multiple Myeloma Patients at the AACR Annual Meeting

April 8, 2022

Oncolytics Biotech® Letter to Shareholders - Update on Recent Progress

April 6, 2022

Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

March 31, 2022

Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort

March 24, 2022

Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep's Stimulation of Natural Killer Cell Anti-Cancer Activity

March 17, 2022

Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual Meeting

March 9, 2022

Oncolytics Biotech® Announces Upcoming Poster Presentation at the AACR Annual Meeting

March 9, 2022

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

March 3, 2022

Oncolytics Biotech® Provides Positive Safety Update on the Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

February 2, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 22 decks. Every deck is listed under its year.